{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["6(Suppl )"],"submitter":["Garcia-Manero G"],"journal":["HemaSphere"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9642083"],"repository":["biostudies-literature"],"pubmed_title":["S129: TAKEAIM LEUKEMIA- A PHASE 1/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA-4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED/REFRACTORY AML OR MDS"],"pmcid":["PMC9642083"],"pubmed_authors":["Zhou L","Lane M","Platzbecker U","Li C","Winer E","Groepper S","Dugan J","Sallman D","Giagounidis A","Metzeler K","Garcia-Manero G","Bohme M","Kubasch A","Verma A","DeAngelo D","von Roemeling R","Tarantolo S","Gotze K","Martinez E"],"additional_accession":[]},"is_claimable":false,"name":"S129: TAKEAIM LEUKEMIA- A PHASE 1/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA-4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED/REFRACTORY AML OR MDS","description":null,"dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jun","modification":"2025-04-26T13:11:18.903Z","creation":"2025-02-19T04:37:55.591Z"},"accession":"S-EPMC9642083","cross_references":{}}